Paper - WANFANG MED ONLINE

You Position: Home > Paper

单核苷酸多态性与卵巢上皮性癌的治疗及预后评估的关系

( views:156, downloads:60 )

Author:: No author available

Journal Title:: Chinese Journal of Obstetrics and Gynecology

Issue:: 11

DOI:: 10.3760/cma.j.issn.0529-567x.2012.11.020

Key Word:: No keyword available

Abstract：卵巢上皮性癌(卵巢癌)是常见的妇科恶性肿瘤,因其起病隐匿、进展迅速,约2/3以上的卵巢癌患者确诊时已至晚期阶段,故而病死率高居妇科肿瘤之首.自人类基因组计划完成全人类基因组测序后,从基因单核苷酸多态性(SNP)角度对卵巢癌进行遗传分子学水平的研究越来越多.SNP是指存在于某一群体而与正常个体的基因组DNA中单个碱基的序列存在差异,并在人群中的分布频率至少要在1％以上[1].近年来,卵巢癌基因、易感基因的SNP在卵巢癌发生及发展过程中的精细作用日益受到研究者的关注.现就基因SNP与卵巢癌的化疗耐药、基因治疗及预后评估等方面的关系综述如下.

Reference

[1]Jyotsna, Batra,Christina M, Nagle,Tracy, O'Mara,etc.A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.[J].2011,11.
[2]Celeste Leigh, Pearce,Jennifer A, Doherty,David J, Van Den Berg,etc.Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.[J].2011,20.
[3]Kedda MA,O'Mara TA,Batra J,etc.Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.[J].2011,14(4).
[4]N J, Risch.Searching for genetic determinants in the new millennium.[J].2000,405(6788).
[5]Nicole D. Fleming,Hasmik Agadjanian,Hoorig Nassanian,etc.Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer[J].2012,118(3).
[6]Catherine M, Phelan,Ya-Yu, Tsai,Ellen L, Goode,etc.Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.[J].2010,19.
[7]Jikai, Yin,Karen, Lu,Jie, Lin,etc.Genetic variants in TGF-β pathway are associated with ovarian cancer risk.[J].2011,6(9).
[8]Dolan ME.Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.[J].2011,17(16).
[9]Ernest K, Amankwah,Qinggang, Wang,Joellen M, Schildkraut,etc.Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.[J].2011,6.
[10]Hefler LA,Zeillinger R,Tong D,etc.Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer.[J].2010,30(9).
[11]Kimchi-Sarfaty C,Oh JM,Kim IW,etc.A "silent" polymorphism in the MDR1 gene changes substrate specificity.[J].2007,315(5811).
[12]Sherman M,Chanock S,Peplonska B,etc.Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.[J].2009,69(6).
[13]Fridley, Brooke L.,Iversen, Ed,Ya-Yu Tsai,etc.A Latent Model for Prioritization of SNPs for Functional Studies.[J].2011,6(6).
[14]Chan H, Han,Yu-Jing, Huang,Karen H, Lu,etc.Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer.[J].2011,30.
[15]Brenton JD,Ng CK,Melnyk N,etc.Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.[J].2010,29(35).
[16]Prema, Peethambaram,Brooke L, Fridley,Robert A, Vierkant,etc.Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome.[J].2011,2(2).
[17]Christoph, Engel,Beatrix, Versmold,Barbara, Wappenschmidt,etc.Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.[J].2010,19.
[18]Marmé,F.,Hielscher,T.,Hug,S.,etc.Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer[J].2012,131(4).
[19]Darb Esfahani S,Gradhand E,Bartel F,etc.An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.[J].2010,70(23).
[20]Darcy KM,Bookman M,Gallion H,etc.Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.[J].2011,122(1).
[21]Rosenberg P,Green H,Soderkvist P,etc.ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.[J].2008,97(6).